This content is machine translated Oral JAK-i in atopic dermatitis Benefits and risks: What does the current data say? Although there have been no recent approvals of oral JAK inhibitors (JAK-i) for atopic dermatitis (AD), some interesting study findings have been published. These shed light on the safety of...…
View Post 9 min This content is machine translated Journal Club: Atopic dermatitis Modern systems therapy – status quo and prospects The therapeutic landscape for atopic dermatitis is changing. New findings have made it possible to develop modern treatment options that selectively target inflammatory signaling pathways. There are currently two modern…
View Post 4 min This content is machine translated "Small Molecules" at AD Current analyses of the pioneer among the JAK-i The first representative of the Janus kinase (JAK) inhibitor class to be approved for atopic dermatitis was baricitinib. In an extensive study program, this selective and reversible inhibitor of JAK-1…
View Post 6 min This content is machine translated Chronic itching Non-trivial – despite proven and new system therapies Chronic pruritus can occur at any age and affect different groups of patients. A guideline-based approach is advisable in order to determine the cause and provide the best possible treatment…
View Post 6 min This content is machine translated Alopecia areata: drug therapy Which method achieves the best hair growth rates? Alopecia areata (AA) manifests as acute or chronic non-scarring hair loss. Diphenylcyclopropenone and Janus kinase inhibitors have a significantly higher remission rate compared with the spontaneous course, especially in severe…
